2 results about "Retina Neovascularization" patented technology

Microparticulate (MP) formulations formed from one or more poly(hydroxyacid) polymers having a molecular weight ranging from 5kD to 60kD, and one or more active agents are injected into the eye of a subject to address eye disorders. The MP formulations assure high drug loading and extended delivery of the active agent of six to twelve months. The active agents may include peroxisome proliferator-activated receptor alpha (PPARα) signaling agonists such as PPARα agonist A190 (IUPAC name 3-((4-((4-fluorobenzyl)oxy)- 3- methylbenzyl)amino)benzoic acid). The formulations have therapeutic and protective effects against retinal degeneration diseases such as age-related macular degeneration (AMD), but may also be used for treating or relieving the symptoms of retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity (ROP), diabetic retinopathy (DR), and diabetic macular edema (DME).

The application provides an animal model of high-oxygen-induced retinal neovascular disease and a preparation method thereof. The method comprises the following steps: placing a mouse born for 3-7 days in an environment with an oxygen concentration of 75-85%, and maintaining for 10-30 days. The method can successfully induce a long-acting retinal neovascular disease model, has a high modeling rate, fewer complications, more persistent retinal neovascular lesions, and a model duration of 55 days. The animal model provides a more optimal model for exploring long-acting anti-retinal neovascular related drugs.